Rise in incidence and prevalence of target conditions, developments in imaging technologies using radiopharmaceuticals, and surge in adoption of SPECT and PET scans have boosted the growth of the Asia-Pacific nuclear medicine market. The market across China dominated in terms of revenue in 2020, accounting for more than one-fourth of the market.
The Asia-Pacific Nuclear Medicine Market was accounted for $4.11 billion in 2020, and is estimated to reach $8.95 billion by 2028, growing at a CAGR of 10.4% from 2020 to 2028.
Covid-19 scenario:
- The Covid-19 pandemic presented several challenges such as a disrupted supply chain and shortage of raw materials.
- The prolonged lockdown in Asian countries and temporary ban on cross-boarder import-export led to distribution problems.
On the basis of modality, the alpha emitters segment is projected to manifest the highest CAGR of 21.0% from 2020 to 2028. However, the SPECT segment held the largest share in 2020, contributing to around three-fifths of the market.
The Asia-Pacific nuclear medicine market report includes an in-depth analysis of the prime market players such as Bracco S.P.A. (Bracco Imaging S.P.A.), Bwx Technologies, Inc. (Nordion, Inc.), Cardinal Health, Inc., Danaher Corporation (GE Healthcare), FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Holdings Corporation), Ion Beam Applications (Ion Beam Applications, SA), Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.), Novartis AG (Advanced Accelerator Applications S.A.), Otsuka Holdings Co., Ltd. (ABX advanced biochemical compounds GmbH), and Siemens Healthcare GmbH.
0 Comments